Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters

Journal of Cancer Research and Clinical Oncology

Volumn 122, Issue 10, 1996, Pages 575-584

  Bokemeyer, Carsten ^a   Kuczyk, Markus A ^b   Serth, Jürgen ^b   Hartmann, Jörg T ^a   Schmoll, Hans Joachim ^b   Jonas, Udo ^b   Kanz, Lothar ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Chemotherapy; P 53 tumour suppressor gene; Prognostic factors; Retroperitoneal lymphadenectomy; Stage I; Testicular cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; ETOPOSIDE; PROTEIN P53; VINBLASTINE;

CLINICAL TRIAL; GERM CELL TUMOR; HUMAN; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEXUAL DYSFUNCTION; TESTIS TUMOR;

EID: 0029811355     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01221188     Document Type: Review

References (85)

1. Albers P, Albers J, Cummings OW, Boris M, Donohue JP, Foster RS (1995a) Flow cytometric and cytophotometric DNA analysis cannot predict subsequent tumour recurrence in pathological stage II A/B non-seminomatous testicular germ cell tumour patients who do not receive adjuvant chemotherapy. Eur J Cancer 31A:848-849
2. Albers P, Ulbright TM, Albers J, Miller GA, Foster RS, Donohue JP (1995b) New prognostic parameters to predict pathological stage A nonseminomatous testicular germ cell tumours (NSGCT). J Urol 153:244 A
3. Allhoff EP, Liedke S, Riese W de, Stief CG, Tanke HJ, Schneider B, Kramer AEJL, Jonas U (1991) Assessment of individual prognosis for patients with NSGCT/CS I. J Urol 145:367 A
4. Atkin NB, Baker MC (1982) Specific chromosome change, i(12p), in testicular tumours. Lancet 2:1349
5. Babaian RJ, Bracken RB, Johnson DE (1981) Complications of transabdominal retroperitoneal lymphadenectomy. Urology 17:126-128
6. Bokemeyer C, Schmoll H-J, Kuczyk, MA, Beyer J, Siegert G (1995) Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer. J Natl Cancer Inst 87:58-60
7. Bokemeyer C, Kuczyk MA, Dunn T, Serth J, Hartmann K, Jonasson J, Pietsch T, Jonas U, Schmoll HJ (1996) Expression of stem cell factor and its receptor c-kit protein in normal testicular tissue and malignant germ-cell tumours. J Cancer Res Clin Oncol 122:301-306
8. Bosl GJ, Dimitrovsky E, Reuter VE, Samaniego F, Rodriguez E, Geller NL, Chaganti RS (1989) Isochromosome of the short arm of chromosome 12. Clinically useful marker for male germ cell tumours. J Natl Cancer Inst 81:1874-1878
9. Bürger RA, Braun MH, Witzsch U, Potratz D, Stöckle M, Hohenfellner R (1993) Automated DNA-image analysis in testicular cancer; value of 5c exceeding rate as prognostic factor. J Urol 149:390 A
10. Chevreau C, Forni M de, Soulie M, Mihura J, Plante P (1991) Is adjuvant chemotherapy a beneficial treatment in stage I high risk nonseminomatous testicular germ cell tumours? Eur J Cancer [Suppl 2] 651 A
11. Costello AJ, Mortensen PH, Stillwell RG (1989) Prognostic indicators for failure of surveillance management of stage I nonseminomatous germ cell tumours. Aust NZ J Surg 59:119-122
12. Cullen MH, Stenning SP, Parkinson MC, Fossa SD, Horwich AH, Kaye SB, Harland SJ, Williams MV, Jakes R (1995) A short course adjuvant chemotherapy in high risk stage I non-seminomatous germ cell tumours of the testis (NSGCT): an MRC (UK) study report. Proc Am Soc Clin Oncol 14:244A
13. De Riese WTW, Walker EB, De Riese C, Jones JA, Foster RS, Donohue JP, Messemer J (1993) Predictive value of proliferative parameters measured by flow cytometry in early stage nonseminomatous germ cell tumours (NSGCT). J Urol 149:962A
14. Donohue JP (1987a) Controversies in testis cancer management. In: Kernion J de, Paulson D (eds.) Genitourinary cancer management. Lea & Febiger Philadelphia pp 161-186
15. Donohue JP (1987b) Management of low clinical stage testis cancer (editorial comment). Urol Clin North Am 14:729-730
16. Donohue JP (1990) Nerve-sparing retroperitoneal lymphadenectomy. Beitr Onkol 40:124-132
17. Donohue JP, Rowland RG (1981) Complications of retroperitoneal lymph node dissection. J Urol 125:338-340
18. Donohue JP, Einhorn LH, Perez JM (1978) Improved management of nonseminomatous testis tumours. Cancer 42:2903-2908
19. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R (1993a) Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965-1989): modifications of technique and impact on ejaculation. J Urol 149:237-243
20. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R (1993b) Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer: review of the Indiana University experience 1965-1989. Br J Urol 71:326-335
21. Dunphy CH, Ayala AG, Swanson DA, Ro JY, Logothetis C (1988) Clinical stage I nonseminomatous and mixed germ cell tumours of the testis. Cancer 62:1202-1206
22. Fernandez EB, Sesterhenn IA, McCarthy WF, Mostofi FK, Moul JW (1994) Proliferating cell nuclear antigen expression to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumours. J Urol 152:1133-1138
23. Fossa SD, Ous S, Abyholm T, Norman N, Loeb N (1985) Posttreatment fertility in patients with testicular cancer. II. Influence of cis-platin-based combination chemotherapy and of retroperitoneal surgery on hormone and sperm cell production. Br J Urol 57:210-214
24. Fossa SD, Ous S, Stenwig AE, Lien HH, Aas N, Kaalhus O (1990) Distribution of retroperitoneal lymph node metastases in patients with non-seminomatous testicular cancer in clinical stage I. Eur Urol 17:107-112
25. Fossa SD, Nesland JM, Waehre H, Amellem O, Pattersen EO (1991) DNA ploidy in the primary tumour from patients with nonseminomatous testicular germ cell tumours clinical stage I. Cancer 67:1984
26. Freedman LS, Parkinson MC, Jones WG, Oliver RTD, Peckham MJ, Read G, Newlands ES, Williams CJ (1987) Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchiectomy alone. Lancet 2:294-298
27. Fung CY, Kalish LA, Brodsky GL, Richie JP, Garnick MB (1988) Stage I nonseminomatous germ cell testicular tumour: prediction of metastatic potential by primary histopathology. J Clin Oncol 6:1467-1473
28. Gibas Z, Prout GR, Sandberg AA (1984) Malignant teratoma of the testis with an isochromosome No. 12, i(12p), as the sole structural cytogenetic abnormality. J Urol 139:762-763
29. Gimmi C, Sonntag R, Brunner K (1990) Adjuvant treatment of high risk (HR) clinical stage I testicular carcinoma (TC) with cisplatin (C), bleomycin (B) and vinblastine (V) or etoposide (E). Proc Am Soc Clin Oncol 8:140
30. Gressler V, Levine L, Vogelzang N (1990) A third option in the management of patients with clinical stage 1, non-seminomatous germ cell tumour? J Clin Oncol 8:4-8
31. Hoskin P, Dilly S, Easton D, Heroic A, Hendry W, Peckham MJ (1986) Prognostic factors in stage I nonseminomatous germ cell testicular tumours managed by orchiectomy and surveillance. Implications for adjuvant chemotherapy. J Clin Oncol 4:1031-1036
32. Jacobson GK, Rorth M, Osterlind K, von der Maase H, Jacobson A, EL Madsen, Pedersen M, Schultz H, Danish Testicular Cancer Study Group (1990) Histopathological features in stage I nonseminomatous testicular germ cell tumours correlated to relapse. APMIS 98:377-382
33. Jewett MAS, Torbey C (1988) Nerve-sparing techniques in retroperitoneal lymphadenectomy in patients with low-stage testicular cancer. Semin Urol 6:233-237
34. Jewett MAS, Kong Y-SP, Golberg SD, Sturgeon JFG, Thomas GM, Alison RE, Gospodarowicz MK (1988) Retroperitoneal lymphadenectomy for testis tumour with nerve sparing for ejaculation. J Urol 139:1220-1224
35. Klepp O, Olsson AM, Henrikson H, Aass N, Dahl O, Stenwig AE, Persson BE, Cavalli-Stahl E, Fossa SD, Wahlquist L (1990) Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. J Clin Oncol 8:509-518
36. Kuczyk MA, Serth J, Bokemeyer C, Allhoff EP, Jonassen J, Kuczyk S, Jonas U (1994) Overexpression of the p53 oncoprotein in carcinoma in situ of the testis. Pathol Res Pract 190:993-998
37. Kuczyk MA, Serth J, Bokemeyer C, Hervatin C, Oelke M, Oelert F, Höfner K, Jonas U (1995) Wertigkeit von Proliferationsstatus (PCNA) und p53-Immunhistochemie als Prognosefaktor für den klinischen Verlauf superfizieller Harnblasenkarzinome. Urologe A 34:146-152
38. Lange PH, Change WY, Fraley EE (1987) Fertility issues in the therapy of nonseminomatous testicular tumors. Urol Clin North Am 14:731-747
39. Lewis DJ, Sesterhenn IA, McCarthy WF, Moul JW (1994) Immunohistochemical expression of p53 tumor suppressor gene protein in adult germ cell testis tumors: clinical correlation in stage I disease. J Urol 152:418-423
40. Madej G, Pawinski A (1991) Risk-related adjuvant chemotherapy for stage I non seminoma of the testis. Clin Oncol R Coll Radiol 3:270-272
41. McLeod DG, Weiss RB, Stablein DM, Muggia FM, Paulson DF, Ellis JH, Spaulding JT, Donohue JP (1991) Staging relationships and outcome in early stage testicular cancer: A report from the Testicular Cancer Intergroup Study. J Urol 145:1178-1183
42. Moul JW, Robertson JE, George SL (1989) Complications of therapy for testicular cancer. J Urol 142:1491-1496
43. Moul JW, Theune SM, Chang EH (1992) Detection of RAS mutations in archival testicular germ cell tumors by polymerase chain reaction and oligonucleotide hybridization. Genes Chromosomes & Cancer 5:109-118
44. Moul JW, Foley JP, Hitchcock CL, Mc Carthy WF, Sesterhenn IA, Becker RL, Griffin JL (1993) Flow cytometric and quantitative histological parameters to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors. J Urol 150:879-883
45. Moul JW, McCarthy WF, Fernandez EB, Sesterhenn IA (1994) Percentage of embryonal carcinoma and vascular invasion predict pathologic stage in clinical stage I nonseminomatous testicular cancer. Cancer Res 54:1-3
46. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B (1989) Mutations in the p53 gene occur in diverse human tumor types. Nature 342:705-708
47. Oliver RTD, Raja MA, Ong J (1992) Pilot study to evaluate impact of a policy of adjuvant chemotherapy for a high risk stage I malignant teratoma on overall relapse rate of stage I patients. J Urol 148:1453-1456
48. Oliver RTD, Ong J, Ostrowski J, Williams M (1993) One versus two courses of adjuvant therapy compared to radiotherapy of surveillance for stage I germ cell tumours. In: Jones WG, Harden P, Appleyard I (eds) Germ cell tumours. III. Elsevier Science, Oxford New York Tokyo, pp 203-205
49. Peckham MJ, Barrett A, Husband JE, Hendry WF (1981) Orchiectomy alone in testicular stage I nonseminomatous germ cell tumors. Lancet 2:678
50. Peng HQ, Hock D, Malkin D, Bailey D, Gallie BL, Bulebul M, Jowett M, Buchanan J, Goss PE (1993) Mutations of the p53 gene do not occur in testis cancer. Cancer Res 3:3574-3578
51. Pietsch T, Serth J, Stanulla M, Kuczyk, MA, Bokemeyer C, Thon WF, Jonas U (1994) Coexpression of stem cell factor and its receptor c-kit in germ cell tumors. J Urol 151:408A
52. Pizzocaro G (1985) Unilateral lymphadenctomy in preoperative clinically negative non-seminoma. In: Khoury S, Küss R, Murphy GP, Chatelain C, Karr JP (eds) Testicular Cancer. Liss, New York, pp 563
53. Pizzocaro G (1991) Management of stage I nonseminoma: rationale for lymphadenectomy. In: Horwich A (ed) Testicular cancer, 1st edn. Chapman & Hall London New York Tokyo, pp 167-173
54. Pizzocaro G, Monfardini S (1984) No adjuvant chemotherapy in selected patients with pathologic stage II nonseminomatous germ cell tumors of the testis. J Urol 131:677-680
55. Pont J, Höltl W, Kosak D (1990) Risk-adapted treatment choice in stage I non-seminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor: a prospective trial. J Clin Oncol 8:16-20
56. Read G, Stenning SP, Cullen MH, Parkinhson MC, Horwich A, Kaye SB (1992) Prospective study of surveillance for stage I testicular teratoma: MRC Testicular Tumour Working Party. J Clin Oncol 10:1762-1768
57. Richie JP (1988) Modified retroperitoneal lymphadenectomy for patients with clinical stage I testicular cancer. Semin Urol 6:216-222
58. Richie JP (1990) Clinical stage I testicular cancer: the role of modified retroperitoneal lymphadenectomy. J Urol 144:1160-1163
59. Rodriguez E, Mathew S, Reuter V, Ilson DH, Bosl GJ, Chaganti RS (1992) Cytogenetic analysis of 124 prospectively ascertained male germ cell tumors. Cancer Res 52:2285-2291
60. Rowland RG, Donohue JP (1988) Testicular cancer: innovations in diagnosis and treatment. Semin Urol 6:223-232
61. Sago AL, Ball TP, Novicki DE (1979) Complications of retroperitoneal lymphadenectomy. Urology 13:241-243
62. Sandemann TF, Yang C (1988) Results of adjuvant chemotherapy for low-stage nonseminomatous germ cell tumors of the testis with vascular invasion. Cancer 62:1471-1475
63. Sarkis AS, Dalbagni G, Cordon - Cardo C, Zhang ZF, Sheinfeld J, Fair WR, Herr HW, Reuter VE (1993) Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 85:53-59
64. Schmoll HJ, Waegener W (1984) Adjuvant therapy in resectable stage II nonseminomatous testicular cancer. In: Jones SE, Salmon SE (eds) Adjuvant therapy of cancer. IV. Grune & Stratton, Orlando, pp 539-548
65. Serth J, Kuczyk MA, Bokemeyer C, Hervatin C, Nafe R, Tan HK, Jonas U (1995) p53 immunohistochemistry as an independent prognostic factor for transitional cell carcinoma of the bladder. Br J Cancer 71:201-205
66. Sesterhenn IA, Weiss RB, Mostofi FK, Stablein DM, Rowland RG, Falkson G, Rivkind SE, Vogelzang NJ (1992) Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: a report from the Testicular Cancer Intergroup Study. J Clin Oncol 10:69-78
67. Skinner DG, Melamud A, Lieskovsky G (1982) Complications of thoraco-abdominal retroperitoneal lymph node dissection. J Urol 127:1107-1110
68. Sogani PC, Whitmore WF, Herr HW (1984) Orchiectomy alone in the treatment of clinical stage I nonseminomatous germ cell tumor of the testis. J Clin Oncol 2:267-270
69. Stauffenberg A, Brensing KA (1990) Veränderungen des Hormonhaushalts durch Chemotherapie. Beitr Onkol, 40:115-123
70. Stephenson RA (1991) Surveillance for clinical stage I nonseminomatous testis carcinoma: rationale and results. Urol Int 46:290-293
71. Strohmeyer T, Peter S, Hartmann M, Munemitsu S, Ackermann R, Ullrich A, Slamon DJ (1991) Expression of the hst-1 and c-kit protooncogenes in human testicular germ cell tumors. Cancer Res 51:1811-1816
72. Strohmeyer TG, Fleischhacker M, Imai Y, Slamon DJ, Koeffler HP (1993) Status of the p53 tumor suppressor gene and the MDM-2 gene in human testicular tumors. J Urol 149:311A
73. Strohmeyer T, Reese D, Press M, Ackermann R, Hartmann M, Slamon D (1995) Expression of c-kit proto-oncogene and its ligand stem cell factor (SCF) in normal and malignant human testicular tissue. J Urol 153:511-515
74. Studer UE, Fey MF, Calderoni A, Kraft R, Mazzuchelli L, Sonntag RW (1993) Adjuvant chemotherapy after orchiectomy in high risk patients with clinical stage I nonseminomatous testicular cancer. Eur Urol 23:444-449
75. Swanson DA, Johnson DE (1989) M.D. Anderson experience with surveillance for clinical stage I disease. In: Johnson DE, Logothetis CJ, Von Eschenbach AC (eds) Systemic therapy for genitourinary cancers. Year Book Medical Publishers, Chicago, pp 304-311
76. Thor AD, Moore DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH, Smith HS (1992) Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-854
77. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J (1992) Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84:883-887
78. Weißbach L, Bode HU (1982) Die modifizierte Lymphadenektomie zur Protektion der Ejakulation. Beitr Onkol 8:133-138
79. Weißbach L, Bussar-Maatz, R (1995) Können Risikofaktoren die Strategien im Stadium I des Nicht-Seminoms bestimmen ? Akt Urol 26:79-88
80. Weißbach L, Sommerhoff C, Struth B (1980) Aussagen zur Fertilität bei Patienten mit germinalen Hodentumoren. Extr Urol 3:159-174
81. Weißbach L, Boedefeld EA for the Testicular Tumor Study Group (1987) Localization of solitary and multiple metastases in stage II nonseminomatous testis tumor as basis for a modified staging lymph node dissection in stage I. J Urol 138:77-82
82. Weißbach L, Boedefeld EA, Horstmann-Dubral B (1990) Surgical treatment of metastatic stage II nonseminomatous testis tumor. J Urol 146:1295-1298
83. Whitmore W (1979) Surgical treatment of adult germinal testis tumor. Semin Oncol 6:55-68
84. Williams SD, Stablein DM, Einhorn LH, Muggia FM, Weiss RB, Donohue JP, Paulson DF, Benner KW, Jacobs EW, Spaulding JT (1987) Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 317:1433-1438
85. Wishnow KI, Dunphy CH, Johnson DE, Ayala AG, Swanson DA, Ro JY, Tenney DM, Eschenbach AC, Babaian RJ (1989) Identifying patients with low risk clinical stage I nonseminomatous testicular tumors who should be treated by surveillance. Urology 34:339-343